Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22051969 | 0.83 | IDO1 (0.52) | IDO1PNMTPRMT5WDR77PLAU | |
| SCHEMBL9926587 | 0.79 | IDO1 (0.48) | IDO1PRMT5WDR77PLAUDRD3 | |
| SCHEMBL26998687 | 0.79 | IDO1 (0.44) | IDO1PRMT5WDR77PLAU | |
| SCHEMBL7255966 | 0.78 | IDO1 (0.56) | IDO1PNMTPRMT5WDR77PLAU | |
| SCHEMBL72445 | 0.74 | IDO1 (0.52) | IDO1PNMTPRMT5WDR77PLAU | |
| SCHEMBL13049209 | 0.74 | IDO1 (0.52) | IDO1PRMT5WDR77DRD3 | |
| SCHEMBL18775646 | 0.72 | IDO1 (0.41) | IDO1PRMT5WDR77PLAU | |
| SCHEMBL8349120 | 0.71 | IDO1 (0.48) | IDO1PRMT5WDR77HTR2ADRD3 | |
| SCHEMBL23979191 | 0.70 | CRHR1 (0.42) | — | |
| SCHEMBL25287428 | 0.70 | KDM1A (0.41) | HTR2AHRH1RETHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129099-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2025-04-24 | — | — | US | disclosed |
| EP-4426707-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-09-21 | — | — | US | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023081290-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4143198-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222614-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129099-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | IDO1 1459/4885PNMT 4339/4885PRMT5 3000/4885 |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | IDO1 1459/4885PNMT 4339/4885PRMT5 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.